Study identifier:CV181-148
ClinicalTrials.gov identifier:NCT01552005
EudraCT identifier:N/A
CTIS identifier:N/A
Description of drug utilization and assessment of impact of Saxagliptin on health status of patients with type 2 diabetes in France
Type 2 diabetes mellitus (T2D)
-
No
Saxagliptin
All
1000
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2016 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to respond to The French Health Authority which has requested BMS France and Astra Zeneca (AZ) France to set-up a long-term cohort study in a representative sample of French Type 2 Diabetes mellitus (T2D) patients treated with Saxagliptin to generate real world data on drug utilization, joint population, non comparative effectiveness and safety
Time Perspective: Ambispective cohort follow by a 18 to 24 month follow up period, Retrospective follow by Prospective.
No locations available
Arms | Assigned Interventions |
---|---|
Population of patients treated with Saxagliptin | Drug: Saxagliptin No Intervention |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.